Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2690 participants.

Also called NCT04937699

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,690 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04937699
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04937699. Randomized; no masking; primary purpose treatment. Start 2023-03-28 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention
Acronym
MATE
Condition
Acute Coronary Syndrome
Intervention (Drug)
Standard-DAPT of Ticagrelor plus aspirin
Intervention (Drug)
Sequential monotherapy of Ticagrelor and clopidogrel
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine (class: other)

Record details

Record id
cardio:ct-nct04937699
Content hash
4459547b1745c6f93f33221687c99a2960436768640e1be847c17fb94e663661